new what caused
AIDS, which, at that time, primarily affected homosexual men. With the hope of
discovering the disease's cause, NIAID launched a multicenter effort to enroll
volunteers at risk for developing AIDS. When the discovery of HIV and its
subsequent link to AIDS occurred shortly thereafter, the focus of the study
shifted toward investigating how the disease progresses and how to prevent it.
The MACS originally was composed of clinical research centers at the
institutions mentioned above and at the University of California at Berkeley.
The Berkeley center left the MACS in 1988 to pursue an independent NIAID-funded
investigation, the San Francisco Men's Health Study.
MACS volunteers are evaluated every six months. Volunteer visits include an
interviewer-administered questionnaire, a physical examination, and the
collection of blood samples for analysis of the immune system and to monitor
volunteers' HIV status.
"It's really comforting to have been a part of this research from the
beginning," says Louis Hughes, Jr., a Baltimore resident who enrolled in the
MACS at the Johns Hopkins University site in 1984. "It's been a bittersweet
struggle, but to see the progress from knowing so little about HIV/AIDS to where
we are today when people with HIV are living longer, better lives is very
exciting." Mr. Hughes, who is HIV-negative, notes that he has lost many friends
to AIDS. "But I know that other friends of mine are benefiting from this
research," he adds.
The MACS has played a crucial role in HIV/AIDS research over the past 15 years.
One of the first major MACS breakthroughs came in 1988, when John P. Phair,
M.D., and colleagues at Northwestern University reported that HIV-infected
individuals' risk of contracting Pneumocystis carinii pneumonia (PCP)
dramatically increased once their CD4+ T-cell levels dropped below 200 cells per
cubic millimeter (mm3) of blood. This discovery provided a rational basis for
initiating treatment to prevent PCPPage: 1 2 3 4 Related medicine news :1
Contact: John Bowersox
NIH/National Institute of Allergy and Infectious Diseases
. NIAID initiates trial of experimental avian flu vaccine2
. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks3
. NIAID begins enrolling volunteers for novel HIV vaccine study4
. NIAID-sponsored clinical trial aims to boost flu vaccine supply5
. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks6
. NIAID launches influenza genome sequencing project7
. NIAID launches program to improve medical tools against emerging infectious diseases8
. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine9
. NIAID rotavirus vaccine licensed for commercialization10
. Second NIAID SARS vaccine candidate helps mice fend off SARS11
. NIAID vaccine protects against SARS virus infection in mice